{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:40:56Z","timestamp":1792269656867,"version":"4.4.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) constitute a serious complication in patients undergoing hematopoietic stem cell transplantation (HSCT), with pediatric patients facing particularly formidable therapeutic challenges. The phase III ATTACK trial demonstrates that sulbactam-durlobactam (SUL-DUR), a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination is non-inferior to colistin and is associated with fewer adverse events in adults. However, evidence for SUL-DUR use in post-transplant pediatric patients remains extremely limited. This article reports the first global case of a pediatric patient who experienced two successive HSCT failures and was successfully salvaged with SUL-DUR combined with meropenem for CRAB associated BSI after failing to respond to high-dose sulbactam (150\u2005mg\/kg\/day) and tigecycline during persistent severe neutropenia, providing a novel strategy for managing resistant bacterial infections in high-risk transplant populations.<\/jats:p>","DOI":"10.3389\/fped.2026.1913512","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:33:06Z","timestamp":1789018386000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Successful salvage therapy with sulbactam-durlobactam combined with meropenem for carbapenem-resistant Acinetobacter baumannii bloodstream infection in a child after failure of allogeneic hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"14","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The who bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.idc.2025.12.001","article-title":"How to treat carbapenem-resistant Acinetobacter baumannii infections: current knowledge and personal viewpoints","volume":"40","author":"Cascio","year":"2026","journal-title":"Infect Dis Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions","volume":"78","author":"Wang","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"dlaf134","DOI":"10.1093\/jacamr\/dlaf134","article-title":"The global epidemiology of carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Boutzoukas","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cmi.2025.02.018","article-title":"Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: a 5-year cohort study in intensive care patients","volume":"31","author":"Karakonstantis","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1781326","DOI":"10.3389\/fmed.2026.1781326","article-title":"Carbapenem-eesistant Acinetobacter baumannii bloodstream infections in critically ill patients: prognostic factors and development of a nomogram","author":"Huang","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/antibiotics11111630","article-title":"Efficacy and safety of colistin versus tigecycline for multi-drug-resistant and extensively drug-resistant gram-negative pathogens-a meta-analysis.","volume":"11","author":"Abushanab","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13756-024-01376-7","article-title":"Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis","volume":"13","author":"Bostanghadiri","year":"2024","journal-title":"Antimicrob Resist Infect Control"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0108624","DOI":"10.1128\/aac.01086-24","article-title":"New perspectives on antimicrobial agents: sulbactam-durlobactam","volume":"69","author":"Pogue","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (attack)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.3390\/jcm15062281","article-title":"Sulbactam-durlobactam in the treatment of bloodstream infection due to carbapenem-resistant Acinetobacter baumannii: a case series and literature review","volume":"15","author":"Li","year":"2026","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1633982","DOI":"10.3389\/fphar.2025.1633982","article-title":"Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: a case report","volume":"16","author":"Fu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12879-023-08789-6","article-title":"Acinetobacter spp. bloodstream infection in hematological patients: a 10-year single-center study","volume":"23","author":"Li","year":"2023","journal-title":"BMC Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"50.e1","DOI":"10.1016\/j.jtct.2021.10.008","article-title":"Bloodstream infections and outcomes following allogeneic hematopoietic cell transplantation: a single-center study","volume":"28","author":"Carreira","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"piaf004","DOI":"10.1093\/jpids\/piaf004","article-title":"Suggested dosing of select beta-lactam agents for the treatment of antimicrobial-resistant gram-negative infections in children","volume":"14","author":"Lockowitz","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics13030261","article-title":"Current therapeutic approaches for multidrug-resistant and extensively drug-resistant Acinetobacter Baumannii infections","volume":"13","author":"Rafailidis","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections","volume":"7","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e01809-20","DOI":"10.1128\/AAC.01809-20","article-title":"Pharmacokinetic and pharmacodynamic profiling of minocycline for injection following a single infusion in critically ill adults in a phase iv open-label multicenter study (acumin)","volume":"65","author":"Lodise","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"111367","DOI":"10.1016\/j.isci.2024.111367","article-title":"Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens","volume":"27","author":"Thacharodi","year":"2024","journal-title":"iScience"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the treatment of ampc beta-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eimce.2022.06.014","article-title":"Executive summary of the consensus document of the Spanish society of infectious diseases and clinical microbiology (seimc) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant gram-negative Bacteria","volume":"41","author":"Pintado","year":"2023","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1913512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:33:08Z","timestamp":1789018388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1913512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":24,"alternative-id":["10.3389\/fped.2026.1913512"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1913512","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1913512"}}